Cost-effectiveness of intensive adjuvant chemotherapy for high-risk breast cancer: Is tailored and dose-escalated chemotherapy with growth factor support (GFS) more costly and less effective than marrow-supported high-dose chemotherapy – results from a randomized study

References

• Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, et al. Marrow supported high dose therapy is not superior compared with tailored FEC in the adjuvant setting to high risk breast cancer. Results of a randomized study. Lancet 2000; 356: 1384–91
   PubMed Web of Science ®Google Scholar
• Chang S, Long SR, Kutikova L, Bowman L, Finley D, Crown WH, et al. Estimating the cost of cancer: Results on basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999–2000. J Clin Oncol 2004; 22: 3524–30
   PubMed Web of Science ®Google Scholar
• Radice D, Redaelli A. Breast cancer management. Quality of life and cost considerations. Pharmacoenonomics 2003; 21: 383–96
   PubMed Web of Science ®Google Scholar
• Dunscombe P, Samant R, Roberts G. A cost-outcome analysis of adjuvant postmastectomy locoregional radiotherapy in high-risk postmenopausal breast cancer patients. Int J Radiat Oncol Biol Phys 2000; 48: 977–82
   PubMedGoogle Scholar
• Brown RE, Hutton J, Burrell A. Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics 2001; 19: 1091–102
   PubMed Web of Science ®Google Scholar
• Higa GM. Aromatase inhibitors for breast cancer: Pharmacoeconomic considerations. Expert Opin Pharmacother 2001; 2: 987–95
   PubMedGoogle Scholar
• Pagano E, Ponti A, Gelormino E, Merletti F, Mano MP. An economic evaluation of the optimal workload in treating surgical patients in a breast unit. Eur J Cancer 2003; 39: 748–54
   PubMedGoogle Scholar
• Verma S, Ilersich AL. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer. Oncologist 2003; 8: 232–40
   PubMed Web of Science ®Google Scholar
• Mello MM, Brennan TA. The controversy over high-dose chemotherapy with autologous bone marrow transplant for breast cancer. Health Aff (Millwood) 2001; 20: 101–17
   PubMed Web of Science ®Google Scholar
• Schulman KA, Stadtmauer EA, Reed SD, Glick HA, Goldstein LJ, Pines JM, et al. Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoetic stem-cell transplantation for metastatic breast cancer. Bone Marrow Trans 2003; 31: 205–10
   PubMed Web of Science ®Google Scholar
• Rodenhuis S, Richel D, van der Wall E, Schornagel JH, Baars JW, Koning CC, et al. Randomised trial of high-dose chemotherapy and haematopoetic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 2003; 352: 515–21
   Google Scholar
• Rodenhius S, Bontenbal M, Beex LV, Wagstaff J, Ricehl DJ, Nooij MA, et al. High dose chemotherapy with hematopoietic rescue for high risk breast cancer. New Eng J Med 2003; 349: 7–16
   PubMedGoogle Scholar
• Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frey D, Booser DJ, et al. Randomised trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast cancer. J Natl Cancer Inst 2000; 92: 225–33
   PubMed Web of Science ®Google Scholar
• Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, et al. Conventional adjuvant chemotherapy with or without high dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Eng J Med 2003; 349: 17–26
   PubMed Web of Science ®Google Scholar
• Elfenbein GJ. Stem cell transplantation for high risk-breast cancer. N Eng J Med 2003; 349: 80–2
   PubMed Web of Science ®Google Scholar
• Wheatley K, Gray RG, Ives NJ. Correspondence. High dose chemotherapy for breast cancer. N Eng J Med 2003; 349: 1476–7
   PubMedGoogle Scholar
• Bergh J, Wiklund T, Erikstein B, Fornander T, Bengtsson N-O, Malmström P, et al. Dosage of adjuvant G-CSF (Filgrastim) supported FEC polychemotherapy based on equivalent hematological toxicity to high risk breast cancer. Ann Oncol 1998; 9: 1–9
   Google Scholar
• Ithaka R, Gentleman R. A language for data analysis and graphics. J Comput Graph Stat 1996; 5: 299–314
   Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet 2005;365:1665–717.
   PubMedGoogle Scholar
• Bergh J. Where next with stem-cell–supported high-dose therapy for breast cancer?. Lancet 2000; 355: 944–45
   PubMedGoogle Scholar
• Champlin RE. Peripheral blood progenitor cells: A replacement for marrow transplantation?. Semin Oncol 1996; 23: 15–21
   PubMed Web of Science ®Google Scholar
• Brice P, Gordin S, Libert O, Marolleau JP, Makki Jextra JM, Extra JM, et al. Influence of the granulocyte growth factor on the cost of bone marrow autografts in oncologic hematology. Presse Medicale 1994; 23: 1512–5
   PubMedGoogle Scholar
• Overgaard M. Radiotherapy as part of multidisciplinary treatment strategy in early breast cancer. Eur J Cancer 2001; 37: 33–43
   PubMedGoogle Scholar
• Faulkner LB, Tucci F, Tamburini A, Tintori V, Lippi AA, Bambi F, et al. G. G-CSF serum pharmacokinetics during peripheral blood progenitor cell mobilization: Neutrophil count-adjusted dosage might potentially improve mobilization and be more cost-effective. Bone Marrow Trans 1998; 21: 1091–5
   PubMedGoogle Scholar
• Kath R, Hartmann M, Hoffken K. Pharmacoeconomic evaluation of high-dose chemotherapy and peripheral blood stem cell support in high-risk or poor-prognosis malignancies. J Cancer Res Clin Oncol 1998; 124: 288–90
   PubMed Web of Science ®Google Scholar
• Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547–55
   PubMed Web of Science ®Google Scholar
• Frey P, Stinson T, Siston A, Knight SJ, Ferdman E, Traynor A, et al. Lack of caregivers limits use of outpatient hematopoetic stem cell transplant program. Bone Marrow Trans 2002; 30: 741–8
   PubMed Web of Science ®Google Scholar
• Bredeson C, Malcolm J, Davis M, Bence-Bruckler I, Kearns B, Huebsch L. Cost analysis of the introduction of PBPC for autologous transplantation: Effect of switching from bone marrow (BM) to peripheral blood progenitor cells (PBPC). Bone Marrow Trans 1997; 20: 889–96
   PubMedGoogle Scholar
• Meisenberg BR, Ferran K, Hollenbach K, Brehm T, Jollon J, Piro LD. Reduced charges and costs associated with outpatient autologous stem cell transplantation. Bone Marrow Trans 1998; 21: 927–32
   PubMed Web of Science ®Google Scholar
• Meisenberg BR, Miller WE, McMillan R, Callgahn M, Sloan C, Brehm T, et al. Outpatient high-dose chemotherapy with autologous stem cell rescue for hematologic and nonhematologic malignancies. J Clin Oncol 1997; 15: 11–7
   PubMed Web of Science ®Google Scholar
• Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradisher WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 2003; 21: 14311–439
   Google Scholar
• Peters WP, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, Richardson PG, et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: A report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol. 2005; 23: 2191–200
   PubMed Web of Science ®Google Scholar
• Beltz SE, Yee GC. Pharmacoeconomics of cancer therapy. Cancer Control 1998; 5: 415–24
   PubMedGoogle Scholar
• Chirikos TN, Ruckdeschel JC, Krischer JP. Economic analysis of cancer treatment costs: Another tool for oncology managers. J Oncol Manag 2001; 10: 11–7
   PubMedGoogle Scholar
• Koopmanschap MA, Touw KC, Rutter FF. Analysis of costs and cost-effectiveness in multinational trials. Health Policy 2001; 58: 175–86
   PubMedGoogle Scholar
• Ridenour TA, Treloar JH, Dean RS. Utility analysis for clinical decision-making in small treatments settings. Int J Neuroscience 2003; 113: 417–30
   PubMed Web of Science ®Google Scholar
• Wilking N, Jönsson B. A pan-European comparison of regarding patient access to cancer drugs. Karolinska Institute, StockholmSweden 2005
   Google Scholar
• Kievit W, Bolter MJ, van der Wilt GJ, Bult P, Thunissen FB, Meijer J, et al. Cost-effectiveness of new guidelines for adjuvant systemic therapy for breast cancer. Ann Oncol 2005; 16: 1874–81
   PubMedGoogle Scholar